Voyager Therapeutics’ (VYGR) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report released on Tuesday morning,RTT News reports. They currently have a $9.00 price objective on the stock, down from their previous price objective of $11.00. Wedbush also issued estimates for Voyager Therapeutics’ FY2029 earnings at ($0.86) EPS.

VYGR has been the subject of several other reports. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a report on Monday, January 27th. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Finally, Citigroup started coverage on Voyager Therapeutics in a research note on Monday, December 2nd. They set a “buy” rating and a $12.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $15.72.

Voyager Therapeutics Stock Down 0.9 %

Shares of VYGR stock opened at $4.38 on Tuesday. Voyager Therapeutics has a 52-week low of $4.00 and a 52-week high of $10.66. The business has a 50-day simple moving average of $5.65 and a 200-day simple moving average of $6.32. The stock has a market cap of $239.28 million, a PE ratio of 6.17 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. During the same quarter in the previous year, the business earned ($0.59) EPS. Sell-side analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Activity at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders have sold 10,778 shares of company stock valued at $58,548 over the last quarter. 4.53% of the stock is owned by insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Several hedge funds have recently made changes to their positions in VYGR. Picton Mahoney Asset Management boosted its stake in shares of Voyager Therapeutics by 71.1% during the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after buying an additional 2,444 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Voyager Therapeutics by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after buying an additional 4,098 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Voyager Therapeutics during the 3rd quarter worth approximately $74,000. Virtu Financial LLC purchased a new position in shares of Voyager Therapeutics during the 4th quarter worth approximately $100,000. Finally, Legal & General Group Plc increased its stake in shares of Voyager Therapeutics by 65.2% during the 4th quarter. Legal & General Group Plc now owns 19,245 shares of the company’s stock worth $109,000 after purchasing an additional 7,597 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.